antithrombotic trialists’ (att) collaboration. lancet 2009;373:1849-60
TRANSCRIPT
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
Design and eligibility criteria of primary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
Serious vascular events in primary prevention trials-proportional effects of aspirin allocation
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
Serious vascularevents in primary
preventionTrials-subgroup
analyses
ATT Collaboration. Lancet 2009;373:1849-60
Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
Selected outcomes in primary
and secondary prevention
trials of aspirin, by sex
ATT Collaboration. Lancet 2009;373:1849-60
Stroke subtypes in primary and
secondary prevention trials
ATT Collaboration. Lancet 2009;373:1849-60
Mortality by cause in primary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
Rate ratios (95% CI) associated with risk factors for selected outcomes in people with no known
vascular disease in primary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
Predicted 5-year absolute eff ects of
allocation to aspirin in different categories of
age and sex in theprimary and
secondary prevention trials (ignoring non-vascular mortality)
ATT Collaboration. Lancet 2009;373:1849-60
Predicted 5-year absolute effects of allocation to aspirin in the primary
prevention trials in different categories of
5-year risk (if untreated)of coronary heart disease
(CHD) (ignoring non-vascular mortality)
ATT Collaboration. Lancet 2009;373:1849-60